Clinical trials in Liepaja – page 4

45 clinical trials in Liepaja, Latvia. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in LatviaKliniskiePetijumi.lv

Liepaja at a glance

clinical trials

Research sites0

Quick filters

45 trials in Liepaja

Open in trial search

Bladder cancer

Not recruiting

Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo

Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo

Latvia

Participants:18–64 years · 65+ years
Substances:Poloxamer 407
Sponsor:Urogen Pharma Ltd.

Contact Research Centre

Abdominal infection+3

Not recruiting

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Resistant Bacterial Infections

Registered drugNo placebo

Study on the Effectiveness and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam for Adults with Resistant Bacterial Infections

Registered drugNo placebo

Latvia

Participants:18–64 years · 65+ years
Substances:Amikacin Sulfate
Sponsor:Meiji Seika Pharma Co. Ltd.

Contact Research Centre

Transitional cell carcinoma

Not recruiting

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo

Latvia

Participants:18–64 years · 65+ years
Substances:Avelumab
Sponsor:Bicycletx Limited

Contact Research Centre

Urinary tract infection

Not recruiting

Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

Registered drug

Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

Registered drug

Latvia

Participants:18–64 years · 65+ years
Substances:Cilastatin
Sponsor:Spero Therapeutics Inc.

Contact Research Centre

Embolism

Not recruiting

Study on REGN7508 for Preventing Blood Clots in Adults After Knee Replacement Surgery

Registered drugNo placebo

Study on REGN7508 for Preventing Blood Clots in Adults After Knee Replacement Surgery

Registered drugNo placebo

Latvia

Participants:18–64 years · 65+ years
Substances:Enoxaparin Sodium
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

Latvia

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Bayer AG

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Study on the Effects of Upadacitinib in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE)

Investigational

Study on the Effects of Upadacitinib in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE)

Investigational

Latvia

Participants:18–64 years
Substances:Upadacitinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Embolism

Not recruiting

Study on REGN9933 for Preventing Blood Clots in Adults After Knee Replacement Surgery

Registered drugNo placebo

Study on REGN9933 for Preventing Blood Clots in Adults After Knee Replacement Surgery

Registered drugNo placebo

Latvia

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Neoplasm

Not recruiting

Study of Olaparib and Pembrolizumab for Patients with Advanced Cancer with HRRm or HRD Mutations

Registered drugNo placebo

Study of Olaparib and Pembrolizumab for Patients with Advanced Cancer with HRRm or HRD Mutations

Registered drugNo placebo

Latvia

Participants:18–64 years · 65+ years
Substances:Olaparib
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Other cities in Latvia

The busiest research cities in the country

All 19 cities in Latvia

Clinical research in Liepaja

What the registry says about research in the country

01 Autoimmune Conditions

Clinical trials focusing on treatments for psoriatic arthritis, ulcerative colitis, and systemic lupus erythematosus. Studies evaluate novel therapies including zasocitinib, eltrekibart, and upadacitinib for improved disease management.

Psoriatic Arthritis Treatment Development
Ulcerative Colitis Management
Lupus Therapy Advancement

Research aims to enhance treatment efficacy and patient outcomes in chronic inflammatory conditions.

02 Cardiovascular Research

Innovative studies targeting atherosclerotic cardiovascular disease and stroke prevention. Trials examine new medications like inclisiran and asundexian for managing cardiovascular risks and preventing major adverse events.

Atherosclerosis Treatment
Stroke Prevention
Blood Clot Management

Focus on reducing cardiovascular events and improving patient outcomes in high-risk populations.

03 Oncology Studies

Research investigating treatments for bladder cancer and prostate cancer. Clinical trials evaluate innovative therapies including UGN-102 and novel combinations for various stages of cancer progression.

Bladder Cancer Treatment
Advanced Prostate Cancer Therapy
Cancer Drug Development

Studies aim to improve treatment options and outcomes for cancer patients.

Back to Latvia All countries